Navigation Links
The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
Date:1/31/2008

WORCESTER, Massachusetts, February 1 /PRNewswire/ --

- ENDORSE Global Findings Highlight the Need to Urgently Implement Hospital-Wide Strategies to Optimize VTE Management: Systematically Assess Patient Risk for VTE and Provide Appropriate Prophylaxis to Prevent VTE

ENDORSE multinational study (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting) published today in the LANCET(1) demonstrates the high prevalence of patients at risk for VTE (according to the ACCP guidelines) in the world: 52% of hospitalized patients surveyed were at risk for VTE, corresponding to 64% of surgical patients and 42% of medical patients.

ENDORSE demonstrates as well, that recommended prophylaxis is only prescribed to 50% of at-risk patients throughout the world, corresponding to 59% of surgical and 40% of medical patients.

With more than 60,000 patients studied in more than 32 countries encompassing 6 continents the scope of ENDORSE is unprecedented. With a wide range of racial, social, economic and health care environment, ENDORSE gives a unique global and local picture about the extent of the hospitalized patient population at risk for VTE and how these patients are managed.

Doctor Fred Anderson, Director of the Center for Outcomes Research at the University of Massachusetts Medical School who conducted the study commented "ENDORSE shows that a substantial proportion of hospitalized patients are at risk for VTE in each of 32 participating countries. Despite these objective data that VTE risk is important on a global scale, the use of recommended prophylaxis is sub-optimal. This is a complex problem, which will require multiple solutions, including local and national programs of education, guideline development, increased reimbursement for prophylaxis, and addition of VTE prevention to the health-care agenda in every country."

VTE is a major public health issu
'/>"/>

SOURCE University of Massachusetts Medical School
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Lancet Publishes Vasogens ACCLAIM Results
2. Vasogens Research Published in European Journal of Neuroscience
3. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
4. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
5. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
6. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
7. Researchers outline structure of largest nonvirus particle ever crystallized
8. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
9. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
10. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
11. Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... DUBLIN , May 27, 2015 Research ... the "Animal Genetics Market by Products, by Testing ... their offering. The global animal genetics market ... 2014 and grow at a CAGR of 8-9% during ... This market is mainly driven by increasing animal protein ...
(Date:5/28/2015)... , May 28, 2015 Celsion Corporation ... it has received commitments from two institutional healthcare investors ... the Company,s common stock in an at-the-market registered direct ... purchase common stock. The Company entered into ... which the Company agreed to sell an aggregate of ...
(Date:5/28/2015)... 28, 2015  PDS Biotechnology Corp. announces preliminary ... targeting HPV-16, has generated strong T-cell responses in ... cancer is treated by surgical removal of lesions ... non-surgical alternative. Results show that it primes and ... target, and kill precancerous and cancerous cells that ...
(Date:5/28/2015)... 28, 2015 CD-adapco, the largest ... software, announced today it is joining the consortium ... provide state-of-the-art engineering simulation tools for analyzing particle ... and experiences in analyzing particle flow that will ... advance the understanding of flow modeling solutions. , ...
Breaking Biology Technology:Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... cooperative research center program (I/UCRC) will "provide a one-stop ... wide range of metamaterials." Dr. David Crouse, associate ... Engineering at The City College of New York, serves ... Participating institutions are The City University of ...
... Inc. (OTCBB: PEDX) announced that the U.S. Centers ... state Medicaid agencies to include PediatRx,s GRANISOL, NDC ... funds the Medicaid and State Children Health Insurance ... health insurance, including prescription drug coverage, to over ...
... 2011 Cellular Dynamics International (CDI), the ... induced pluripotent stem cell (iPSC) lines, today announced it ... patented definitive endoderm differentiation technology from ViaCyte, Inc. ... CDI will apply this patented methodology in the development ...
Cached Biology Technology:Grove School professor leads new metamaterials center 2Grove School professor leads new metamaterials center 3Grove School professor leads new metamaterials center 4GRANISOL™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement 2GRANISOL™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement 3GRANISOL™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement 4Cellular Dynamics Licenses Technology From ViaCyte 2Cellular Dynamics Licenses Technology From ViaCyte 3
(Date:5/7/2015)... GOTHENBURG, Sweden , May 7, 2015 /PRNewswire/ ... new touch fingerprint sensors, FPC1022 and FPC1035, FPC,s ... FPC1022 and FPC1035 are mainly considered for integration ... decreased size gives smartphone OEMs increased possibilities to ... portfolio. The decreased size also improves possibilities for ...
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... in the Proceedings of the National Academy of Sciences ... from the Kennedy Krieger Institute and four collaborating institutions, identified ... to the development of glaucoma and its resulting vision loss. ... head, the point where the cables that carry information from ...
... researchers led by Daniel J. Rader, MD, associate ... and Therapeutics, has received a $6 million grant ... molecular genetics of atherosclerotic cardiovascular disease. The team,s ... Plasma Lipids and Cardiovascular Disease," was selected to ...
... vomiting hairballs or refusing to eat probably isn,t being finicky ... is a good chance that the cat is acting sick ... new research suggests. Healthy cats were just as likely ... leave waste outside their litter box in response to changes ...
Cached Biology News:New research reveals unexpected biological pathway in glaucoma 2Penn Medicine researcher receives $6 million grant for cardiovascular disease study 2Even healthy cats act sick when their routine is disrupted 2Even healthy cats act sick when their routine is disrupted 3Even healthy cats act sick when their routine is disrupted 4Even healthy cats act sick when their routine is disrupted 5
Request Info...
... Accurate To score SNPs, ... sequencing, the gold standard in DNA analysis. ... The polymorphic locus can be confirmed by ... DNA sequencing also provides sequence context information, ...
... top-of-the-line PowerPac 3000 power supply is ... ideal for isoelectric focusing, DNA sequencing, ... electrophoresis, western blotting, and submerged gel ... of powre, the PowerPac 3000 power ...
... GT cell and PowerPac basic power supply are ... acids in agarose gels. The wide mini format ... and electrodes, and leveling bubble. The PowerPac basic ... of 10-300 V, 4-400 mA, and 75 W. ...
Biology Products: